Antibodies Market
The global antibodies market is estimated to account for US$ 147,385.1 Mn in terms of value and is expected to reach US$ 384,011.6 Mn by the end of 2027. Antibody, also called as immunoglobulin, is a protein produced by plasma cells in response to specific antigens. These Antibodies can be used as therapeutic as well as diagnostic purposes for several indications, including cancers, autoimmune disorders, inflammatory & infectious diseases and others.
1. The adoption of antibody-based drugs for the treatment of cancer has significantly increased. Monoclonal antibody therapeutics offer high specificity, activity, favorable pharmacokinetics, and standardized manufacturing processes. 2. Moreover, antibodies can increase immune response against cancer cells through complement-dependent cytotoxicity or antibody dependent cellular cytotoxicity. 3. The use of antibodies as a diagnostic reagents for the identification of disease markers or proteins based on immunoassays has decreased. 4. This is attributed to increasing accuracy of molecular diagnostic tools.
For more details, visit-https:// cmiblogdailydose.blogspot.com/2022/07/antibodies-componentof-immunee-system.html Global Antibodies Market: Competitive Landscape Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Sanofi, Eli Lilly and Co., Iovance Biotherapeutics, Inc., Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd.
Thank You!